BACKGROUND
CD19 chimeric antigen receptor T-cell (CAR-T) therapy has achieved remarkable results in treating patients with refractory or relapsed diffuse large B-cell lymphoma (R/R DLBCL). Nevertheless, certain limitations still persist. This study focuses on the impact of extranodal involvement before treatment on the...
Ji-Le Liu, Mo-Han Zhao, Xiu Liu et al.· Leukemia research : a Forum...· 0 citations
Focusing on the disease characteristics of elderly AML, this narrative review summarizes the clinical efficacy of venetoclax, critically examines the multifaceted mechanisms of venetoclax resistance, and discusses current and emerging therapeutic strategies to overcome this resistance.
Jin-Lin Zhang, Ji-Le Liu, Mo-Han Zhao et al.· Clinical and Translational M...· 0 citations
Relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the leading cause of treatment failure in high-risk acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), yet effective maintenance strategies are currently lacking. The combination of chidamide (CHI) and venetoclax (VEN) re...
C. Lyu, Hao-Tian Meng, Yedi Pu et al.· Annals of Hematology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.